Abivax - ADR
ABVX
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.21B
Close$
$7.58
91.4% downside
Current Fair Value
91.4% downsideOvervalued by 91.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.21 Billion |
|---|---|
| Enterprise Value | $9.82 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.65 |
| Beta | -0.25 |
| Outstanding Shares | 79,647,974 |
Return
| Return on Equity | -133.12% |
|---|---|
| Return on Assets | -105.49% |
| Return on Invested Capital | -104.99% |
Valuation & Multiples
| P/E Ratio | -16.77 |
|---|---|
| PEG | -101.53 |
| Price to Sales | - |
| Price to Book Ratio | 22.0 |
| Enterprise Value to Revenue | 4902.93 |
| Enterprise Value to EBIT | -23.95 |
| Enterprise Value to Net Income | -21 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 21, 2026
EPS Estimate
$-0.98
Average shareholder expectationRevenue Estimate
$799,166
Average shareholder expectationNext Earnings Call
Expected Date
December 21, 2026
EPS Estimate
$-1.27
Average shareholder expectationRevenue Estimate
$771,422
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 53.54% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.88%▼ 78.14% |
|---|---|
| Total Invested | $69.30M▼ 99.03% |
| Investors Holding | 9▼ 358.00% |
ESG Score
No data
About Abivax
69 employees
CEO: Marc de Garidel Based in Paris, France, ABIVAX Société Anonyme is a biopharmaceutical company dedicated to the discovery and optimization of novel drug treatments. Their research and development efforts primarily target inflammatory conditions, infectio...